Zhang · Oxidative medicine and cellular longevity 2018 · Preclinical animal and in vitro experiment · n=?

Activating the PGC-1 α /TERT Pathway by Catalpol Ameliorates Atherosclerosis via Modulating ROS Production, DNA Damage, and Telomere Function: Implications on Mitochondria and Telomere Link.

Cited 69 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal and in vitro study without human data.

PubMed 30046372 · doi:10.1155/2018/2876350 · record verified 2026-08-28

What was done

Researchers investigated the effects of catalpol (an iridoid glucoside from Rehmannia glutinosa L.) on atherosclerosis, oxidative stress, DNA damage, and telomere shortening in LDLr -/- mice. They also evaluated oxidized LDL-treated macrophages transfected with PGC-1α or TERT siRNA to assess pathway involvement, and measured PGC-1α promoter activity using a dual-luciferase reporter assay.

What was found

The abstract reports no numerical values, sample sizes, or effect estimates. The authors reported that catalpol reduced atherosclerosis, oxidative stress, DNA damage, and telomere shortening in LDLr -/- mice. In oxLDL-treated macrophages, catalpol lowered oxidative stress and DNA damage while preserving telomere function via the PGC-1α/TERT pathway, and directly enhanced PGC-1α promoter activity.

Why it matters

This work identifies the PGC-1α/TERT pathway connecting mitochondrial function and telomere maintenance as a potential target in atherosclerosis and provides a mechanistic basis for catalpol in preclinical models.

Limits

The study is entirely preclinical, relying on a mouse knockout model and cell cultures that may not reflect human disease. The abstract provides no sample sizes, dosages, treatment durations, or quantitative outcome measures.

Cited by